Clinical Trial: Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional




Official Title: Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.

Brief Summary:

To evaluate the chemical efficacy and safety of intranasally administered peptide T on neurocognitive function in HIV seropositive individuals.

Previous studies have shown that treatment with peptide T can result in cognitive improvement in HIV-infected patients.

Patients are randomized to receive either peptide T or placebo for the first 6 months. All patients then receive open-label peptide T for approximately 6 additional months. Neuropsychologic tests are used to determine drug effects.